Pfizer On Paxlovid: "There's Still A Long Way To Go"
Access to the COVID-19 treatment is broadening, but Pfizer says there is still work to do when it comes to getting the antiviral to patients quickly.
You may also be interested in...
Some products are still going strong, while others that once generated blockbuster revenues have faded away, as companies develop next-generation antivirals and vaccines.
The company announced data showing the two-antibody drug had strong activity against Omicron BA.4, BA.5 and BA.2.12.1, but on the US market it would compete against oral drugs.
Giving prescribing authority to pharmacists could improve access to the antiviral for patients at high risk for severe COVID-19. Comirnaty financial outlook is also strengthened based on new US contract.